Vir Biotechnology: Pay

Vir Biotechnology paid its 4 named executives $13.8M in total in FY2025 (Dec). CEO Marianne De Backer, M.Sc., Ph.D., MBA was paid $7.8M of that.

Pay$100 in the stock at the end of FY22 → $24
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Marianne De Backer, M.Sc., Ph.D., MBAPresident, Chief Executive Officer and Director
FY2025 (Dec)
FY2024 (Dec)
FY2023 (Dec)
3 years
Mark Eisner, M.D., M.P.H.Executive Vice President and Chief Medical Officer
FY2025 (Dec)
FY2024 (Dec)
2 years
Jason O’Byrne, MBAExecutive Vice President and Chief Financial Officer
FY2025 (Dec)
FY2024 (Dec)
2 years
Vanina de Verneuil, J.D.Executive Vice President, General Counsel and Corporate Secretary
FY2025 (Dec)
FY2024 (Dec)
2 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 6 peers with pay on file was $5.4M. The CEO of Vir Biotechnology was paid $7.8M, 44% above the median.

  1. 1Ultragenyx Pharmaceutical
  2. 2Novavax
  3. 3Vir Biotechnology
  4. 4Beam Therapeutics
  5. 5Intellia Therapeutics
  6. 6Denali Therapeutics
  7. 7Relay Therapeutics
  8. 8Allogene Therapeutics, Inc.Not disclosed
  9. 9Arrowhead PharmaceuticalsNot disclosed
  10. 10Dynavax TechnologiesNot disclosed
  11. 11Editas Medicine Inc.Not disclosed
  12. 12IGM BiosciencesNot disclosed
  13. 13Iovance BiotherapeuticsNot disclosed
  14. 14Janux TherapeuticsNot disclosed
  15. 15REGENXBIO Inc.Not disclosed
  16. 16Replimmune GroupNot disclosed
  17. 17XencorNot disclosed
  18. 18iTeos TherapeuticsNot disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.